Avalyn's Inhaled Nintedanib Shows Promising Safety Profile in Phase 1 Trials for IPF Treatment
Key Insights
Avalyn Pharma (search) has successfully completed Phase 1 clinical trials of AP02, an inhaled formulation of nintedanib, demonstrating safety and favorable tolerability at all tested dose levels in healthy volunteers and IPF (search) patients.
The novel inhaled delivery approach aims to maximize therapeutic impact while minimizing systemic exposure, potentially addressing key limitations of current IPF (search) treatments that are associated with significant toxicities.
Based on these positive results, Avalyn (search) plans to advance AP02 into Phase 2 clinical trials for idiopathic pulmonary fibrosis (search), with full data presentation scheduled for the American Thoracic Society 2025 International Conference in May.
Avalyn Pharma (search) Inc. announced today that its novel inhaled formulation of nintedanib (AP02) demonstrated safety and favorable tolerability in Phase 1 clinical trials, positioning the therapy to advance into Phase 2 development for idiopathic pulmonary fibrosis (search) (IPF (search)).
The Cambridge, Massachusetts-based clinical-stage biopharmaceutical company reported positive topline data from both single-ascending dose (SAD) and multiple-ascending dose (MAD) studies conducted in healthy adult volunteers and patients with IPF (search).
"We are excited to complete this innovative set of clinical trials for AP02, where we assessed lung exposure in both studies of the inhaled compared to oral nintedanib," said Lyn Baranowski, Chief Executive Officer of Avalyn (search). "Through its enhanced drug delivery directly to the lungs, our approach allows us to address the underlying pathophysiology of the disease and positions AP02 as a potential future standard-of-care for patients with IPF (search)."
Trial Design and Results
The most recently completed Phase 1 trial enrolled 60 healthy adult volunteers and was structured in three parts:
- A single-ascending dose (SAD) portion evaluating AP02 at 2.0 mg, 4.0 mg, and 8.0 mg once-daily (QD)
- A multi-ascending dose (MAD) portion assessing twice-daily (BID) dosing at the same dose levels over seven days
- A bronchoalveolar lavage (BAL) component measuring lung exposure following a single 4.0 mg AP02 dose across three timepoints
The company reports that AP02 was safe and well-tolerated at all dose levels tested. Complete data on safety, tolerability, and pharmacokinetics from the two Phase 1 studies will be presented at the American Thoracic Society 2025 International Conference in May 2025.
Addressing Unmet Needs in IPF Treatment
IPF (search) represents a significant unmet medical need, characterized by progressive scarring of lung tissue, declining lung function, reduced exercise capacity, and diminished quality of life. The condition is largely untreatable and associated with high mortality rates.
While current approved therapies can slow disease progression, they come with significant toxicities that often limit their use and dosing. Avalyn (search)'s approach with AP02 aims to overcome these limitations by delivering nintedanib directly to the lungs, potentially maximizing therapeutic impact while minimizing systemic exposure.
"There is a clear need to bring treatment options to patients that maximize therapeutic impact while minimizing systemic exposure and transform the disease from a fatal diagnosis into a manageable condition," noted the company in its announcement.
Pipeline and Development Strategy
AP02 represents Avalyn (search)'s second clinical program. The company's lead candidate, AP01, is an optimized inhaled formulation of pirfenidone currently being evaluated in the ongoing MIST Phase 2b study for progressive pulmonary fibrosis (search) (PPF).
According to the company, AP01 has been assessed in over 150 individuals with various forms of pulmonary fibrosis (search) and has demonstrated clinical proof-of-concept with improved efficacy and safety compared to historical data with existing therapies.
Based on the positive Phase 1 results for AP02, Avalyn (search) plans to advance the inhaled nintedanib formulation into a Phase 2 clinical program specifically for IPF (search) patients. This development represents a significant step forward in the company's mission to reimagine pulmonary fibrosis (search) treatment through novel inhaled formulations of approved medicines.
The Potential Impact
If successful in later-stage trials, AP02 could potentially transform the treatment landscape for IPF (search) by addressing the disease directly at its source while minimizing the systemic side effects that often limit patient adherence to current therapies.
The inhaled approach tackles the underlying pathophysiology of pulmonary fibrosis (search) at its source and is designed to reduce systemic exposure while delivering medication directly to the site of disease. This targeted delivery system could potentially allow for more effective dosing regimens and improved patient outcomes.
As Avalyn (search) prepares to present the full dataset at the upcoming American Thoracic Society conference, the pulmonary fibrosis (search) community will be watching closely to see if this novel approach could indeed represent a significant advancement in the management of this challenging condition.